Isofol Medical AB

ST:ISOFOL Sweden Biotechnology
Market Cap
$16.50 Million
Skr185.11 Million SEK
Market Cap Rank
#27189 Global
#362 in Sweden
Share Price
Skr0.66
Change (1 day)
+0.00%
52-Week Range
Skr0.58 - Skr2.08
All Time High
Skr33.00
About

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.

Isofol Medical AB (ISOFOL) - Total Liabilities

Latest total liabilities as of December 2025: Skr21.52 Million SEK

Based on the latest financial reports, Isofol Medical AB (ISOFOL) has total liabilities worth Skr21.52 Million SEK as of December 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Isofol Medical AB - Total Liabilities Trend (2011–2025)

This chart illustrates how Isofol Medical AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Isofol Medical AB Competitors by Total Liabilities

The table below lists competitors of Isofol Medical AB ranked by their total liabilities.

Company Country Total Liabilities
Champion Technology Holdings Ltd
PINK:CPIHF
USA $192.90 Million
FM Global Logistics Holdings Bhd
KLSE:7210
Malaysia RM439.04 Million
Ynvisible Interactive Inc
OTCQB:YNVYF
USA $1.46 Million
Painchek Ltd
AU:PCK
Australia AU$3.26 Million
Earth Tech Environment Public Company Limited
BK:ETC
Thailand ฿841.10 Million
LGMS Berhad
KLSE:0249
Malaysia RM12.51 Million
Opter AB
ST:OPTER
Sweden Skr13.27 Million
Izotropic Corporation
OTCQB:IZOZF
USA $5.95 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Isofol Medical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.19 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Isofol Medical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Isofol Medical AB (2011–2025)

The table below shows the annual total liabilities of Isofol Medical AB from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 Skr21.52 Million +5.14%
2024-12-31 Skr20.47 Million +6.83%
2023-12-31 Skr19.16 Million -65.15%
2022-12-31 Skr54.99 Million -33.86%
2021-12-31 Skr83.13 Million +1.92%
2020-12-31 Skr81.56 Million +96.24%
2019-12-31 Skr41.56 Million +76.53%
2018-12-31 Skr23.54 Million +29.06%
2017-12-31 Skr18.24 Million +8.65%
2016-12-31 Skr16.79 Million +98.59%
2015-12-31 Skr8.46 Million +240.10%
2011-12-31 Skr2.49 Million --